Mirum Pharmaceuticals, Inc.
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
About
CEO
Mr. Christopher Peetz
Employees
311
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
950 Tower Lane, Foster City, CA 94404, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 26, 2025 | — | — | — | — |
| Nov 12, 2024 | -0.45 | -0.30 | 0.15 | -33.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 7 |
| Average estimate | — | -0.26 | — | -0.52 |
| Low estimate | — | -0.46 | — | -1.55 |
| High estimate | — | -0.08 | — | 1.00 |
| Last year EPS | — | -0.54 | — | -1.42 |
[stock_revenue_estimate]
Growth estimates
Current qtr
60.860%
Next qtr. (Mar 2025)
52.590%
Current year
63.910%
Next year (Dec 2025)
63.270%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 186.37M | 77.06M | 19.14M | — | — |
| Cost of revenue | 47.04M | 12.37M | 1.90M | — | — |
| Gross profit | 139.34M | 64.69M | 17.24M | — | — |
| Operating expense | |||||
| Research & development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M |
| Selling general and admin | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M |
| Non operating interest income | |||||
| Income | 13.74M | 3.86M | 366,000 | 1.56M | 2.23M |
| Expense | 15.11M | 15.98M | 17.59M | 335,000 | — |
| Other income expense | -51.90M | 1.27M | 106.69M | -192,000 | -21,000 |
| Pretax income | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M |
| Tax provision | 991,000 | -6.41M | 37,000 | 6,000 | 21,000 |
| Net income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M |
| Basic EPS | -4.00 | -4.01 | -2.77 | -4.09 | -4.58 |
| Diluted EPS | -4.00 | -4.02 | -2.77 | -4.09 | -4.58 |
| Basic average shares | 40.89M | 33.84M | 30.32M | 25.25M | 11.49M |
| Diluted average shares | 40.89M | 33.84M | 30.32M | 25.25M | 11.49M |
| EBITDA | -87.41M | -123.76M | -65.03M | -102.31M | -52.21M |
| Net income from continuing op. | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 286.33M | 28.00M | 31.34M | 142.09M | 11.97M |
| Other short term investments | — | 123.72M | 125.20M | 89.73M | 104.69M |
| Accounts receivable | 67.97M | 23.99M | 3.27M | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | 22.31M | 5.57M | 1.51M | — | — |
| Prepaid assets | — | — | 5.27M | 4.53M | 2.70M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 10.94M | 8.95M | 5.27M | 4.53M | 2.70M |
| Non current assets | |||||
| Properties | 706,000 | 914,000 | 981,000 | 3.24M | 3.73M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | 252.93M | 58.95M | 18.74M | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 252.93M | 58.95M | 18.74M | — | — |
| Investments and advances | — | — | 4.98M | — | 23.29M |
| Other non current assets | 4.17M | 101.38M | 101.79M | 1.27M | 324,000 |
| Total liabilities | 397.95M | 210.87M | 174.44M | 68.77M | 16.36M |
| Current liabilities | |||||
| Accounts payable | 7.42M | 8.69M | 9.17M | 3.15M | 3.35M |
| Accrued expenses | 50.89M | 36.90M | 20.13M | 8.61M | 7.11M |
| Short term debt | 1.10M | 931,000 | 711,000 | 636,000 | 397,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 20.94M | 14.66M | 9.99M | 4.80M | 2.22M |
| Other current liabilities | — | 1.09M | 2.00M | 1.26M | — |
| Non current liabilities | |||||
| Long term debt | 307.04M | 1.26M | 1.90M | 2.63M | 3.25M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 3.85M | 4.53M | 17,000 | 29,000 | 36,000 |
| Shareholders equity | |||||
| Common stock | 5,000 | 4,000 | 3,000 | 3,000 | 2,000 |
| Retained earnings | -556.24M | -392.82M | -257.16M | -173.17M | -69.90M |
| Other shareholders equity | 1.64M | -217,000 | -35,000 | 83,000 | 129,000 |
| Total shareholders equity | 248.67M | 142.04M | 120.21M | 172.10M | 130.35M |
| Additional paid in capital | 803.26M | 535.07M | 377.40M | 345.18M | 200.12M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M |
| Depreciation | 10.83M | 3.24M | 595,000 | 623,000 | 324,000 |
| Deferred Taxes | — | -6.58M | — | — | — |
| Stock-Based Compensation | 35.02M | 27.01M | 23.09M | 12.55M | 6.07M |
| Other Non-Cash Items | 56.54M | 15.52M | -90.03M | 335,000 | — |
| Accounts Receivable | -43.97M | -20.73M | — | — | — |
| Accounts Payable | 30.78M | 7.64M | 22.66M | 3.68M | 10.06M |
| Other Assets & Liabilities | -5.84M | -4.29M | -1.66M | -1.15M | -277,000 |
| Operating Cash Flow | -80.06M | -113.85M | -129.34M | -87.23M | -36.38M |
| Investing Activities | |||||
| Capital Expenditures | -109,000 | -278,000 | -24,000 | -225,000 | -281,000 |
| Net Intangibles | -20.00M | — | -19.00M | — | — |
| Net Acquisitions | -212.76M | — | — | — | — |
| Purchase of Investments | -27.33M | -132.32M | -198.03M | -74.56M | -152.00M |
| Sale of Investments | 153.00M | 140.30M | 157.60M | 112.66M | 24.50M |
| Investing Cash Flow | -87.20M | 7.70M | 67.55M | 37.87M | -127.78M |
| Financing Activities | |||||
| Long-Term Debt Issuance | 305.30M | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — |
| Other Financing Charges | -195.86M | -5.55M | 64.45M | 49.42M | — |
| Financing Cash Flow | 326.13M | 101.82M | 71.37M | 181.29M | 127.18M |
| Other Cash Details | |||||
| End Cash Position | 286.33M | 128.00M | 131.34M | 142.09M | 11.97M |
| Income Tax Paid | 125,000 | — | — | 11,000 | 21,000 |
| Interest Paid | 6.82M | — | — | — | — |
| Free Cash Flow | -91.05M | -120.41M | -151.78M | -89.30M | -39.64M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Gilead Fund | Sep 30, 2024 | 1,771,533 | 92.62M | 3.69% |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | Sep 30, 2024 | 1,665,883 | 87.09M | 3.47% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,407,511 | 73.58M | 2.93% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,098,016 | 57.40M | 2.29% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 932,953 | 48.77M | 1.94% |
| Janus Henderson Global Life Sciences Fund | Sep 30, 2024 | 828,132 | 43.29M | 1.73% |
| Price (T.Rowe) New Horizons Fund | Sep 30, 2024 | 768,367 | 40.17M | 1.60% |
| Janus Henderson Triton Fund | Sep 30, 2024 | 712,389 | 37.24M | 1.48% |
| Legg Mason Clearbridge Small Cap Growth Fd | Oct 31, 2024 | 648,193 | 33.89M | 1.35% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 588,847 | 30.78M | 1.23% |
Article
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Jan 30, 2025
Article
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?
Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jan 24, 2025
Article
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
Jan 16, 2025
